Not significant now for Progen but certainly significant for...

Not significant now for Progen but certainly significant for other drugs such as Solbec's SBP002 if they successfully progress through Phase 1/11A clinical trials & commence 11B trials in the near future.

With fantastic clinical data already available on Special Access patients & successful completion of Phase 1 safety tolerability, dosage and pharmacokinetics, Solbec are well positioned to move relatively quickly into Phase 11 trials.